Scott Demarest

Scott Demarest

Auto-generated profile, based on publicly available information

Scott Demarest

Children's Hospital Colorado, Precision Medicine Institute, Aurora, CO, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2019 in Epilepsia
Verified
Journal Article
Closed access
PDF file
SDScott T. Demarest
Scott T. Demarest
HOHeather E. Olson
Heather E. Olson
AMAngela Moss
Angela Moss
EPElia Pestana‐Knight
Elia Pestana‐Knight
XZXiaoming Zhang
Xiaoming Zhang
TBTim A. Benke
Tim A. Benke


3 November 2017 in Epilepsia
Verified
Journal Article
Open access
PDF file
SDScott T. Demarest
Scott T. Demarest
RSRenée A. Shellhaas
Renée A. Shellhaas
WGWilliam D. Gaillard
William D. Gaillard
CKCynthia Keator
Cynthia Keator
KNKatherine C. Nickels
Katherine C. Nickels
TCthe Pediatric Epilepsy Research Consortium
the Pediatric Epilepsy Research Consortium
Summary: Objective: The multicenter National Infantile Spasms Consortium prospective cohort was used to compare outcomes and phenotypic features of patients with infantile spasms with and without hypsarrhythmia.Methods: Patients aged 2 months to 2 years were enrolled prospectively with new‐onset infantile spasms. Treatment choice and categorization of hypsarrhythmia were determined clinically at each site. Response to therapy was defined as resolution of clinical spasms (and hypsarrhythmia if present) without relapse 3 months after initiation.Results: Eighty‐two percent of patients had hypsarrhythmia, but this was not associated with gender, mean age, preexisting developmental delay or epilepsy, etiology, or response to first‐line therapy. Infants with hypsarrhythmia were more likely to receive standard treatment (adrenocorticotropic hormone, prednisolone, or vigabatrin [odds ratio (OR) 2.6, 95% confidence interval (CI) 1.4–4.7] and preexisting epilepsy reduced the likelihood of standard treatment (OR3.2, 95%CI1.9–5.4). Hypsarrhythmia was not a determinant of response to treatment. A logistic regression model demonstrated that later age of onset (OR1.09 per month, 95%CI1.03–1.15) and absence of preexisting epilepsy (OR1.7, 95%CI1.06–2.81) had a small impact on the likelihood of responding to the first‐line treatment. However, receiving standard first‐line treatment increased the likelihood of responding dramatically: vigabatrin (OR5.2 ,95%CI2–13.7), prednisolone (OR8, 95%CI3.1–20.6), and adrenocorticotropic hormone (ACTH;OR10.2, 95%CI4.1–25.8) .Significance: First‐line treatment with standard therapy was by far the most important variable in determining likelihood of response to treatment of infantile spasms with or without hypsarrhythmia.

28 May 2022 in CNS Drugs
Verified
Journal Article
Open access
PDF file
WHWilliam Hong
William Hong
IHIsabel Haviland
Isabel Haviland
EPElia Pestana-Knight
Elia Pestana-Knight
JWJudith L. Weisenberg
Judith L. Weisenberg
SDScott Demarest
Scott Demarest
HOHeather E. Olson
Heather E. Olson
Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a developmental and epileptic encephalopathy with infantile-onset epilepsy. Most individuals with CDD develop refractory epilepsy with multiple seizure types. Management of seizures in CDD remains challenging for clinicians given the highly refractory nature of seizures and the limited number of disease-specific studies that offer a high level of evidence. Epileptic spasms are the most common seizure type in CDD and are more often refractory to standard first-line treatment than are spasms of other etiologies. In other seizure types, the effectiveness of antiseizure medications is limited and wanes over time. Ketogenic diet and palliative surgical treatments have both had mixed results in observational studies. When treating refractory seizures in CDD, we recommend carefully balancing seizure control and treatment-related side effects to optimize each individual’s overall quality of life. Clinical trials of medications targeting epilepsy in CDD have been conducted, and additional investigational small molecules, gene therapy, and other disease-modifying therapies are in development for CDD.

1 July 2021 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
GCGemma L. Carvill
Gemma L. Carvill
TMTyler Matheny
Tyler Matheny
JHJay Hesselberth
Jay Hesselberth
SDScott Demarest
Scott Demarest

29 November 2023 in Epilepsia
Verified
Journal Article
Open access
HOHeather E. Olson
Heather E. Olson
SASam Amin
Sam Amin
NBNadia Bahi‐Buisson
Nadia Bahi‐Buisson
ODOrrin Devinsky
Orrin Devinsky
EMEric D. Marsh
Eric D. Marsh
SDScott Demarest
Scott Demarest
Objective: In the placebo‐controlled, double‐blind phase of the Marigold study (NCT03572933), ganaxolone significantly reduced major motor seizure frequency (MMSF) in patients with cyclin‐dependent kinase‐like 5 deficiency disorder (CDD). We report 2‐year safety and clinical outcomes data from the open‐label extension (OLE) phase of Marigold.Methods: Patients with CDD who completed the double‐blind phase were eligible to continue in the OLE. Efficacy assessments included MMSF reduction from prerandomization baseline, responder rates, and Clinical Global Impression–Improvement scores, including assessment of seizure intensity and duration (CGI‐CSID). Safety assessments included treatment‐emergent adverse events (TEAEs) and TEAEs leading to discontinuation.Results: Of 101 patients who enrolled in Marigold, 88 (87.1%) entered the OLE (median age = 5 years, 79.5% female). Median 28‐day MMSF at baseline was 50.6. At 2 years in the OLE (months 22–24), MMSF was reduced by a median of 48.2% (n = 50); when missing data were imputed, median reduction in MMSF was 43.8% using a mixed effects model and 27.4% using a last observation carried forward model. During months 22–24, 23 of 50 (46.0%) patients experienced reductions in MMSF of ≥50%; 12 of 50 (24.0%) patients experienced MMSF reductions of ≥75%. During months 22–24, 40 of 49 (81.6%) patients were rated by caregivers as having improvement in seizure‐related outcomes based on CGI‐CSID scores. Thirty‐seven patients discontinued ganaxolone due to lack of efficacy (n = 13), withdrawal by caregiver (n = 12), adverse event (n = 10), physician decision (n = 1), or death (n = 1; unrelated to study drug). The most common treatment‐related TEAEs were somnolence (17.0%), seizure (11.4%), and decreased appetite (5.7%). Patients reported serious TEAEs (n = 28, 31.8%); those reported in ≥3% of patients were seizure (n = 6), pneumonia (n = 5), acute respiratory failure (n = 3), aspiration pneumonia (n = 3), and dehydration (n = 3).Significance: Sustained reductions in MMSF at 2 years in the OLE support the efficacy of ganaxolone in seizures associated with CDD. Safety findings in the OLE were consistent with the double‐blind phase.